Nucleoside Metabolic Inhibitor drugs compared

Compare all 13 Nucleoside Metabolic Inhibitor drugs side by side, used for conditions such as breast neoplasms, basal cell carcinoma, colonic neoplasms. They share one FDA-defined mechanism but differ in approved uses, prescription status, brand-vs-generic options, price, and FDA recall-safety record — which our independent rating scores. The highest-rated is tolak.

4 of 13 drugs in this class carry a pharmaranks safety score, ranging 68–74 out of 100 — computed from FDA recall records, not from reviews.

Rated against independent sources·Last updated June 7, 2026·How we rate

Top-rated nucleoside metabolic inhibitor: 1. Tolak · 2. Azacitidine · 3. Cytarabine

Nucleoside Metabolic Inhibitor drugs compared side by side, with pharmaranks' FDA recall-safety rating
Drug	Generic	Form	Status	Used for	Safety ratingFDA recall-based	Pharmacy pays
Tolak	Fluorouracil	Topical	Prescription	Breast Neoplasms, Basal Cell Carcinoma	74/100	$1
Azacitidine	—	Injectable	Prescription	Anemia, Refractory, Anemia, Sideroblastic	72/100	—
Cytarabine	—	Injectable	Prescription	Leukemia, Lymphoma	72/100	—
Arranon	Nelarabine	Injectable	Prescription	Leukemia, T-Cell	68/100	—
Capecitabine	—	Tablet	Prescription	Breast Neoplasms, Colorectal Neoplasms	Not yet rated	$14
Decitabine	—	Injectable	Prescription	Myelodysplastic Syndromes	Not yet rated	—
Efudex	Fluorouracil	Topical	Prescription	Breast Neoplasms, Basal Cell Carcinoma	Not yet rated	$1
Favlyxa	Fluorouracil	Injectable	Prescription	Breast Neoplasms, Basal Cell Carcinoma	Not yet rated	$1
Fluorouracil	—	Topical	Prescription	Breast Neoplasms, Basal Cell Carcinoma	Not yet rated	$1
Inlexzo	Gemcitabine Hydrochloride	System	Prescription	Breast Neoplasms, Carcinoma, Non-Small-Cell Lung	Not yet rated	$600
Nelarabine	—	Injectable	Prescription	Leukemia, T-Cell	Not yet rated	—
Onureg	Azacitidine	Tablet	Prescription	Anemia, Refractory, Anemia, Sideroblastic	Not yet rated	—

The safety rating column is unique to pharmaranks — an independent 0–100 score from FDA regulatory recall data. Higher is safer. Not medical advice.

Best nucleoside metabolic inhibitor by condition

for breast neoplasms for basal cell carcinoma for colonic neoplasms for head and neck neoplasms for keratosis for pancreatic neoplasms

Full ranking · 13 drugs

Frequently asked questions

What is the Nucleoside Metabolic Inhibitor drug class?

Nucleoside Metabolic Inhibitor is an FDA Established Pharmacologic Class (EPC) — a group of drugs that share a mechanism of action. pharmaranks lists 13 Nucleoside Metabolic Inhibitor products, each independently rated.

Are all Nucleoside Metabolic Inhibitor drugs the same?

No. Nucleoside Metabolic Inhibitor drugs share the same core mechanism — that is why they sit in one FDA class — but they differ in their approved uses, available forms, whether they are prescription or over-the-counter, brand-vs-generic options and price, and their FDA recall-safety record.

What conditions do Nucleoside Metabolic Inhibitor drugs treat?

Per NIH RxClass drug-classification data, Nucleoside Metabolic Inhibitor drugs are used for conditions including breast neoplasms, basal cell carcinoma, colonic neoplasms, head and neck neoplasms, keratosis, pancreatic neoplasms.

Which Nucleoside Metabolic Inhibitor drug is best-rated?

By our independent rating, tolak currently ranks highest among Nucleoside Metabolic Inhibitor drugs. Ratings are based on FDA regulatory (recall-safety) data — always consult a professional.

Sources: the Nucleoside Metabolic Inhibitor class definition and its member drugs come from the U.S. NLM RxClass (Established Pharmacologic Class); how the class works is summarized from Gemcitabine — LiverTox, NCBI Bookshelf (NIH). Ratings are pharmaranks’ independent FDA recall-safety analysis.